Benzylisoquinoline Alkaloid (BIA) Precursor Producing Microbes, and Methods of Making and Using the Same

Abstract

Host cells that are engineered to produce benzylisoquinoline alkaloid (BIAs) precursors, such as norcodaurine (NC) and norlaudanosoline (NL), are provided. The host cells may have one or more engineered modifications selected from: a feedback inhibition alleviating mutation in a enzyme gene; a transcriptional modulation modification of a biosynthetic enzyme gene; an inactivating mutation in an enzyme; and a heterologous coding sequence. Also provided are methods of producing a BIA of interest or a precursor thereof using the host cells and compositions, e.g., kits, systems etc., that find use in methods of the invention.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]Pursuant to 35 U.S.C. § 119 (e), this application claims priority to the filing date of U.S. Provisional Patent Application Ser. No. 61 / 899,496 filed on Nov. 4, 2013; the disclosure of which application is herein incorporated by reference.GOVERNMENT RIGHTS[0002]This invention is made with Government support under grant No. 1066100 awarded by the National Science Foundation. The Government has certain rights in this invention.INTRODUCTION[0003]Benzylisoquinoline alkaloids (BIAs) are a large group of secondary metabolites from plants and other organisms. These molecules have therapeutic functions in the human body, ranging from the established analgesic and antitussive properties of morphine and codeine, to novel activities against cancer and infection observed for molecules such as berberine and sanguinarine. Supply of all these BIA molecules so that they are available to researchers and physicians is of interest. The number of synthetic re...

AI Technical Summary

Benefits of technology

This patent describes how to modify host cells to produce compounds called benzylisoquinoline alkaloids (BIAs), such as norcoclaurine and norlaudanosoline. These modifications can be made through various means like feedback inhibition alleviating mutations or transcriptional modulation of biosynthetic enzyme genes. The patent also provides methods for using these modified host cells and compositions to produce BIAs of interest or precursors thereof.

Problems solved by technology

The number of synthetic reactions and requirements for selective stereochemistry means that chemical synthesis of BIAs is low yielding and not a viable means for large-scale production.

Even for end product metabolites like morphine, accumulation occurs only within specialized cells in the buds and vascular tissue and requires harsh chemical processing of harvested plant material during the extraction process, which may yield less than 2% morphine by dry weight.

Images